Xeris Biopharma Holdings, Inc. (XERS) Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDT
Company Participants
John Shannon – CEO & Director
Steven Pieper – Chief Financial Officer
Conference Call Participants
Jenna Davidner – Barclays Bank PLC, Research Division
Presentation
Jenna Davidner
Barclays Bank PLC, Research Division
All right. I think we’re all set.
Good morning. It’s still morning. Good morning, and welcome to the Barclays Miami Healthcare Conference. My name is Jenna Davidner. I’m one of the analysts here on the Specialty Pharmaceuticals team. And on stage with me, I have Xeris Biopharma. And from the company, we have the CEO, John Shannon. And on the end, we have Steve Pieper, the CFO.
Thank you, guys, for joining, and welcome to the conference.
John Shannon
CEO & Director
Thanks for having us.
Question-and-Answer Session
Jenna Davidner
Barclays Bank PLC, Research Division
So maybe just to level set the conversation, John, can you just give investors that are less familiar a brief overview of the company and your current product portfolio?
John Shannon
CEO & Director
Yes. I’ll just go really high level because I know we’re going to dig into some of this. So Xeris is a — it’s a fast-growing commercial biopharma company. We have 3 commercial products on the market, Gvoke for hypoglycemia. It’s a rescue pen for hypoglycemia, basically an EpiPen for diabetics.
Keveyis. Keveyis is for primary periodic paralysis, which is an ultra-rare hereditary genetic disorder. We can talk a little bit about that asset in a little bit. And then Recorlev. Recorlev is for hypercortisolemia and Cushing’s syndrome, which is our big grower in the business.
On top of that, we have XP-8121, which is our next potential blockbuster, and that’s a once-weekly subcu levothyroxine for hypothyroidism. And that’s Phase III ready. We’re going to get that
